Plasma Carrier Proteins as Supramolecular Nanovectors for Cancer Therapy: The Trojan Horse Approach
Open Access
Abstract
Conventional chemotherapeutics often suffer from poor aqueous solubility, short circulation half-lives, lack of tumor selectivity, and present dose-limiting systemic toxicity. This perspective examines the Trojan Horse Approach (THA), in which plasma carrier proteins (PCPs) are exploited as discrete, non-covalent supramolecular hosts for chemotherapeutic agents, and discusses its potential to overcome the limitations of both free drugs and conventional protein nanoparticles. Two principal strategies for assembling ex vivo drug–protein complexes are discussed: (i) molecular recognition, in which drugs occupy native ligand-binding pockets, and (ii) molecular anchoring, in which drugs are conjugated to high-affinity anchor ligands. The perspective critically assesses the current state of the art, distinguishes different levels of experimental validation, and discusses the major limitations and barriers to clinical translation. Structural, biochemical, and pharmacological evidence is examined for human serum albumin, transferrin, transthyretin, alpha-1-acid glycoprotein, alpha-fetoprotein, lactoferrin, and other plasma proteins. When appropriately designed and validated, protein-based complexes may preserve the native protein structure while conferring improved drug solubility, protection from premature metabolism, prolonged systemic circulation and enhanced tumor accumulation via combined passive and active targeting. PCPs represent a versatile and underexploited toolbox for cancer drug delivery. Expanding the repertoire of protein carriers, applying in silico rational design to guide the selection and optimization of drug–protein complexes, and exploring the use of patient-derived autologous proteins may open new opportunities for more effective and personalized therapies.Keywords
Funding Information
- Fondazione Italiana per la Ricerca sul Cancro (33286-2025)
This publication has 142 references indexed in Scilit:
- Advances on Albumin‐Based Carriers for Anticancer Drug DeliveryAdvanced NanoBiomed Research, 2025
- Structural and in vitro anticancer properties of the kaempferol–lactoferrin complexFood Science & Nutrition, 2024
- Combining Solid‐State NMR with Structural and Biophysical Techniques to Design Challenging Protein‐Drug ConjugatesAngewandte Chemie International Edition, 2023
- Micro and nanotechnologies: The little formulations that couldBioengineering & Translational Medicine, 2022
- Protein Nanoparticles: Uniting the Power of Proteins with Engineering Design ApproachesAdvanced Science, 2022
- A Bio‐Conjugated Fullerene as a Subcellular‐Targeted and Multifaceted Phototheranostic AgentAdvanced Functional Materials, 2021
- Single Protein Encapsulation: Single Protein Encapsulated Doxorubicin as an Efficacious Anticancer Therapeutic (Adv. Therap. 11/2020)Advanced Therapeutics, 2020
- Investigating the interaction of anticancer drug temsirolimus with human transferrin: Molecular docking and spectroscopic approachJournal of Molecular Recognition, 2018
- Albumin Carriers for Cancer Theranostics: A Conventional Platform with New PromiseAdvanced Materials, 2016
- Human Blood Plasma Proteins2008